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Abstract
Introduction The endoscopic laser balloon ablation system
(EAS) is a relatively novel technique to perform pulmonary
vein isolation (PVI) in the treatment of atrial fibrillation (AF).
The present study aimed to report the results of the first 50
patients treated in the Netherlands with the EAS in terms of
procedural characteristics and AF-free survival.
Methods Fifty patients successfully underwent EAS PVI.
Median follow-up was 17 months. Mean age was 56 years,
82 % had paroxysmal AF.
Results 99 % of the pulmonary veins were successfully iso-
lated with the EAS. Mean procedure time was 171 min and
mean fluoroscopy time was 36 min. One procedure was
complicated by a temporary phrenic nerve palsy (2%). During
follow-up, 58 % of patients remained free of AF without the
use of antiarrhythmic drugs.
Conclusion PVI with EAS is associated with a low risk of
complications and a medium-term AF-free survival compara-
ble with other PVI techniques.
Keywords Atrial fibrillation . Ablation . Pulmonary vein
isolation . Laser balloon ablation
Introduction
Pulmonary vein isolation (PVI) has become an important
treatment modality for atrial fibrillation (AF) [1, 2] although
AF recurrences can occur [3]. Several PVI techniques have
been developed [4, 5] in an attempt to increase AF-free
survival, among which the endoscopic laser balloon ablation
system (EAS) [6, 7]. The EAS consists of a flexible, compliant
balloon for sustained wall contact and an adjustable laser
beam for ablation independent of tissue contact. The present
study aims to report the procedural characteristics and AF-free
survival after EAS PVI of the first 50 patients treated with the
EAS in the Netherlands.
Methods
Fifty consecutive patients who underwent a primo PVI using
the EAS in our centre between December 2011 and December
2013 were included in a prospective registry. The prospective
registry has been approved by the Institutional Review Board
and all patients consented to their data being registered.
Preprocedural care
All patients underwent transoesophageal echocardiography to
rule out left atrial (LA) thrombus prior to the procedure.
Patients stopped using anticoagulants and were ‘bridged’with
low-molecular-weight heparin until the day of ablation, in
accordance with local guidelines.
The endoscopic laser balloon
The EAS (CardioFocus, Marlborough, MA, USA) is a
balloon-based catheter system. Its characteristics have been
described previously [7, 8]. The EAS was manoeuvred to each
pulmonary vein (PV) ostium under fluoroscopic guidance
(Fig. 1). A ring of atrial myocardium antral to the PV was
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exposed by varying the EAS balloon inflation size. Laser
energy was delivered to the exposed ring of atrial tissue. After
a full circle was completed, the EAS was retracted from the
PV. The ablation procedure is also illustrated in an online
movie (online movie). A circular mapping catheter was intro-
duced to assess persistent electrical connection between the
PV and the left atrium. If any existed, the EAS was re-
introduced to the PV, and additional lesions were applied by
the operator. No adenosine testing was performed. An oesoph-
ageal temperature probe (SensiTherm, St Jude Medical, USA)
was inserted, and energy delivery was instantaneously termi-
nated when the temperature exceeded 39.0 °C. During ablation
of the right-sided PVs, stimulation of the phrenic nerve (using
20 mA at 2.9 ms) was performed, with immediate cessation of
energy delivery once capture was diminished or lost.
Follow-up
Patients visited the outpatient clinic at 3, 6, 12, 18 and
24 months after PVI, including 24-h Holter ECG. AF recur-
rence was defined in accordance with European guidelines
[1]. In all patients, antiarrhythmic drugs were ceased 3 months
after the PVI.
Study endpoints
The primary endpoint of our study was AF-free survival after
EAS PVI. Secondary endpoints were: acute PVI, procedure
time, ablation time and fluoroscopy time. The safety endpoint
was major or minor complications within 30 days of the
procedure as described in European guidelines [1].
Statistical analysis
Continuous variables were expressed as mean with standard
deviation in case of normal distribution or median with inter-
quartile range when not normally distributed. Statistical anal-
ysis was performed using IBM SPSS statistics version 20
(IBM inc., Armonk, NY, USA).
Results
Baseline characteristics of the 50 consecutive patients are
displayed in Table 1. Mean age was 56 years, 82 % had
paroxysmal AF. No LA thrombi were found during the pre-
operative transoesophageal echocardiogram. There were 2
left-sided and 1 right-sided common PVs and there were 2
right-sided accessory PVs.
Ablation results
In 198 out of 199 PVs (99.5 %), acute PVI was achieved. One
common left-sided PV could not be isolated due to a temper-
ature rise of the oesophagus. One procedure was converted to
radiofrequency catheter ablation after ablation of the right
upper PV was complicated by a phrenic nerve palsy, which
did not prolong hospital stay and had fully recovered after
Fig. 1 Laser balloon ablation. This figure displays the fluoroscopic setup
of EAS PVI. The EAS has been inflated in the left upper PV. EAS:
endoscopic laser balloon ablation system; PVI: pulmonary vein isolation;
PV: pulmonary vein
Table 1 Baseline characteristics
Patient characteristic Total (n=50)
Gender female (%) 28 %
Age (years) 55.9 (±10.7)
BMI (kg/m2) 26.9 (±3.6)
Persistent AF 18 %
AF duration (years) 7.0 (±6.5)
Failed AADs (range) 1.4 (0–4)
LA ventral-dorsal dimension (mm) 41.1 (±3.9)
LVEF (%) 58.8 (±3.2)
History of hypertension 30 %
History of diabetes mellitus 6 %
Data are presented as percentages or means±their SD or ranges where
appropriate; BMI body mass index; AF atrial fibrillation; AADs antiar-
rhythmic drugs; LA left atrial; LVEF left ventricular ejection fraction
Table 2 Procedural characteristics
Procedure time (min) 170 (±40)
Ablation time (min) 61 (±28)
Fluoroscopy time (min) 36 (±10)
Data are presented as mean±their SD
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6 months. This was the only complication we observed (2 %).
Table 2 displays the procedural characteristics of all patients.
Follow-up
After a median follow-up of 17.3 (interquartile range: 12.9–
19.5) months, 58 % of patients were free of AF after a single
EAS PVI without the use of antiarrhythmic drugs.
Discussion
The present study reports the results of the first 50 patients
treated with the EAS in the Netherlands. Acute PVI can be
achieved virtually always, with a low risk of complications.
Moreover, medium-term AF-free survival seems to be com-
parable with other PVI techniques.
The EAS combines a compliant balloon design, an endo-
scope for visualisation of PV antral tissue and a power-
adjustable laser beam. Previous reports have shown that acute
PVI can be achieved virtually always with the EAS, which
was also observed in the present study [8, 9]. In the present
study, the complication rate is low (2 %), which is consistent
with previous reports [7, 9].
Although PVI is an important treatment modality for AF,
the medium-term AF-free survival is still 60–80 %, after PVI
using different techniques, such as radiofrequency catheter
ablation [3] and cryoballoon ablation [4]. In the present study,
AF-free survival after a single EAS PVI attempt was 58 %,
which is in line with a previous report [9], although there are
other EAS studies reporting a higher AF-free survival [10, 11].
Potentially, a learning curve may, in part, have affected the
AF-free survival in the current study. A randomised trial will
provide further evidence of the AF-free survival after EAS
[12]. Based on the current literature, the AF-free survival rate
after EAS PVI seems to be comparable with other techniques.
AF recurrences are generally regarded as recurrence of
electrical conduction over the PV-LA junction [13, 14]. Dura-
ble lesion sets therefore remain pivotal in improving medium-
term AF-free survival after PVI. The medium-term success
percentage suggests the lesion sets created with the EAS are
not persistent. This was also suggested in another study [10],
which reported that 62 % of the studies patients had 4 isolated
PVs 3 months after the initial EAS PVI procedure.
Future studies should be aimed at identifying factors that are
associated with AF-free survival after EAS PVI. Although the
EAS consists of a compliant balloon, the catheter-tissue contact
may be suboptimal in some patients, limiting the operator’s
ability to deliver circular, transmural lesion sets which may
influence AF-free survival. Moreover, in case of insufficient
occlusion or ablation near to a blood pool, ablation energy had
to be reduced. One study [15] showed high-energy EAS ablation
was favourable to low-energy EAS ablation in terms of persistent
electrical conduction over the PV-LA junction and AF-free sur-
vival after PVI. Although highly speculative, these factors may
explain the medium-term AF-free survival in the present study.
Conclusion
The EAS is a promising technique with a high acute PVI success
rate and a low risk of complications. Medium-term AF-free
survival after EAS PVI is comparable with other PVI techniques.
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